Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New psoriasis drug shows promise in major trial

NCT ID NCT03370133

Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called bimekizumab in 567 adults with moderate to severe plaque psoriasis. Participants received either bimekizumab, a placebo, or another active drug. The main goal was to see how well bimekizumab cleared skin lesions after 16 weeks. Results showed significant improvement in skin clearing compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

567 people

The number who actually took part.

Started

Dec 2017

Finished

Dec 2019

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must be at least 18 years of age * Chronic plaque psoriasis (PSO) for at least 6 months prior to the Screening Visit * Psoriasis Area Severity Index (PASI) \>=12 and body surface area (BSA) affected by PSO \>=10% and Investigator's Global Assessment (IGA) score \>=3 on a 5-point scale * Subject is a candidate for systemic PSO therapy and/or phototherapy * Female subject of child bearing potential must be willing to use highly effective method of contraception Exclusion Criteria: * Subject has an active infection (except common cold), a recent serious infection, or a history of opportunistic or recurrent chronic infections * Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection * Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection * Subject has any other condition, including medical or psychiatric, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in the study * Presence of active suicidal ideation or positive suicide behavior * Presence of moderately severe major depression or severe major depression * Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic plaque psoriasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriasis psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic plaque psoriasis Moderate-to-severe chronic plaque psoriasis Psoriatic arthritis

Contacts and locations

Locations

  • Ps0009 002

    Westmead, Australia

  • Ps0009 004

    Fremantle, Australia

  • Ps0009 005

    Phillip, Australia

  • Ps0009 009

    Woolloongabba, Australia

  • Ps0009 050

    Brussels, Belgium

  • Ps0009 051

    Loverval, Belgium

  • Ps0009 052

    Liège, Belgium

  • Ps0009 205

    Osnabrück, Germany

  • Ps0009 208

    Frankfurt am Main, Germany

  • Ps0009 209

    Darmstadt, Germany

  • Ps0009 210

    Friedrichshafen, Germany

  • Ps0009 211

    Hamburg, Germany

  • Ps0009 212

    Heidelberg, Germany

  • Ps0009 213

    Mahlow, Germany

  • Ps0009 214

    Erlangen, Germany

  • Ps0009 217

    Schweinfurt, Germany

  • Ps0009 218

    Bonn, Germany

  • Ps0009 253

    Orosháza, Hungary

  • Ps0009 254

    Budapest, Hungary

  • Ps0009 255

    Budapest, Hungary

  • Ps0009 259

    Szekszárd, Hungary

  • Ps0009 300

    Roma, Italy

  • Ps0009 303

    Roma, Italy

  • Ps0009 350

    Warsaw, Poland

  • Ps0009 351

    Warsaw, Poland

  • Ps0009 357

    Kielce, Poland

  • Ps0009 358

    Katowice, Poland

  • Ps0009 362

    Bialystok, Poland

  • Ps0009 367

    Wroclaw, Poland

  • Ps0009 369

    Bialystok, Poland

  • Ps0009 370

    Wroclaw, Poland

  • Ps0009 371

    Bydgoszcz, Poland

  • Ps0009 372

    Lodz, Poland

  • Ps0009 374

    Poznan, Poland

  • Ps0009 400

    Moscow, Russia

  • Ps0009 402

    Moscow, Russia

  • Ps0009 403

    Moscow, Russia

  • Ps0009 404

    Saint Petersburg, Russia

  • Ps0009 550

    Manchester, United Kingdom

  • Ps0009 551

    Dundee, United Kingdom

  • Ps0009 552

    Liverpool, United Kingdom

  • Ps0009 553

    Edgbaston, United Kingdom

  • Ps0009 555

    Salford, United Kingdom

  • Ps0009 556

    Cardiff, United Kingdom

  • Ps0009 600

    Kurume, Japan

  • Ps0009 601

    Fukuoka, Japan

  • Ps0009 602

    Shinagawa-Ku, Japan

  • Ps0009 603

    Sapporo, Japan

  • Ps0009 604

    Minatoku, Japan

  • Ps0009 605

    Bunkyō City, Japan

  • Ps0009 606

    Takaoka, Japan

  • Ps0009 607

    Chiyoda City, Japan

  • Ps0009 608

    Itabashi-Ku, Japan

  • Ps0009 609

    Kobe, Japan

  • Ps0009 610

    Chūōku, Japan

  • Ps0009 611

    Osaka, Japan

  • Ps0009 612

    Shinjuku-Ku, Japan

  • Ps0009 613

    Shimotsuke, Japan

  • Ps0009 614

    Osaka, Japan

  • Ps0009 615

    Sumida City, Japan

  • Ps0009 616

    Tsu, Japan

  • Ps0009 617

    Sendai, Japan

  • Ps0009 618

    Shinjuku-Ku, Japan

  • Ps0009 619

    Gifu, Japan

  • Ps0009 620

    Hamamatsu, Japan

  • Ps0009 621

    Nagoya, Japan

  • Ps0009 622

    Matsumoto, Japan

  • Ps0009 623

    Morioka, Japan

  • Ps0009 624

    Obihiro, Japan

  • Ps0009 625

    Nankoku, Japan

  • Ps0009 626

    Shinjuku-Ku, Japan

  • Ps0009 627

    Itabashi-Ku, Japan

  • Ps0009 628

    Shinjuku-Ku, Japan

  • Ps0009 629

    Asahikawa, Japan

  • Ps0009 650

    Surrey, Canada

  • Ps0009 651

    Richmond Hill, Canada

  • Ps0009 652

    Oakville, Canada

  • Ps0009 653

    Toronto, Canada

  • Ps0009 657

    Waterloo, Canada

  • Ps0009 673

    Halifax, Canada

  • Ps0009 900

    West Des Moines, Iowa, 50265, United States

  • Ps0009 901

    Portsmouth, New Hampshire, 03801, United States

  • Ps0009 903

    Ocala, Florida, 34471, United States

  • Ps0009 905

    Overland Park, Kansas, 66215, United States

  • Ps0009 906

    Boca Raton, Florida, 33486, United States

  • Ps0009 907

    Miami, Florida, 33144, United States

  • Ps0009 908

    East Windsor, New Jersey, 08520, United States

  • Ps0009 909

    Boynton Beach, Florida, 33437, United States

  • Ps0009 910

    Bakersfield, California, 93309, United States

  • Ps0009 911

    Plainfield, Indiana, 46168, United States

  • Ps0009 912

    Coral Gables, Florida, 33134, United States

  • Ps0009 913

    New York, New York, 10029-65, United States

  • Ps0009 914

    San Antonio, Texas, 78213, United States

  • Ps0009 915

    St Louis, Missouri, 63117, United States

  • Ps0009 917

    Troy, Michigan, 48084, United States

  • Ps0009 918

    Tampa, Florida, 33612, United States

  • Ps0009 919

    San Diego, California, 92103, United States

  • Ps0009 920

    Portland, Oregon, 97210, United States

  • Ps0009 921

    Ormond Beach, Florida, 32174, United States

  • Ps0009 922

    Baton Rouge, Louisiana, 70809, United States

  • Ps0009 923

    Albuquerque, New Mexico, 87106, United States

  • Ps0009 924

    Houston, Texas, 77004, United States

  • Ps0009 941

    Alpharetta, Georgia, 30022, United States

  • Ps0009 946

    Phoenix, Arizona, 85032, United States

  • Ps0009 958

    Omaha, Nebraska, 68144, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.